Phase 1, multicentre, open-label, dose finding trial of forodesine in patients with relapsed B-cell chronic lymphocytic leukemia.

Trial Profile

Phase 1, multicentre, open-label, dose finding trial of forodesine in patients with relapsed B-cell chronic lymphocytic leukemia.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 02 Apr 2010

At a glance

  • Drugs Forodesine (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Sponsors Mundipharma International
  • Most Recent Events

    • 02 Apr 2010 Planned end date changed from 1 Feb 2010 to 1 May 2009 as reported by ClinicalTrials.gov.
    • 02 Apr 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 05 Aug 2008 Actual start date has changed from Mar 2008 to Jul 2008 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top